Efficacy of Cytoreg in the Treatment of Diabetic Foot Disease
Summary: Under compassionate-use protocol, 10 DFU patients received oral Cytoreg (5ml/day in juice) for 30 days, with 5 also getting weekly topical washes. Oral+topical achieved 80% complete closure (4/5); oral-only 50% (2/4). Significant increases in arterial hemoglobin and pO2 (p<0.05); decreases in HbA1c, AST/ALT, creatinine, urea. Cytoreg's antiseptic action cleared contaminants without damaging tissue, promoting scarring.
Key Highlights:
- Groups: Oral+topical 80% closure; oral-only 50% (one dropout).
- Biomarkers: ↑ pO2/hemoglobin; ↓ HbA1c, liver/kidney markers (p<0.05).
- Method: 30-day protocol; Saint Elian wound monitoring; no SOC differences.
- Safety: Excellent tolerability; no AEs.
- Implications: Warrants expanded trials for Cytoreg in DFUs.
Keywords: Cytoreg, diabetic foot, compassionate use, oral antiseptic, pO2